As of January 22, 2025, Gubra A/S (GUBRA.CO) has a market cap of $1.42 billion USD. According to our data, Gubra A/S is ranked No.4681 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $1.42 B |
-0.00%
|
Dec 30, 2024 | $1.42 B |
399.20%
|
Dec 29, 2023 | $0.28 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Novo Nordisk
NVO
|
$335.53 B |
64.154 B
|
Denmark
|
Eli Lilly
LLY
|
$676.92 B |
0.020 M
|
USA
|
Sanofi
SNY
|
$128.55 B |
0.003 M
|
France
|
AstraZeneca
AZN
|
$211.43 B |
0.005 M
|
UK
|
Pfizer
PFE
|
$148.34 B |
-0.006 M
|
USA
|
Merck
MRK
|
$242.59 B |
0.007 M
|
USA
|
Bristol-Myers Squibb
BMY
|
$115.86 B |
0.003 M
|
USA
|
GlaxoSmithKline
GSK
|
$68.38 B |
0.002 M
|
UK
|
Amgen
AMGN
|
$147.53 B |
0.002 M
|
USA
|
Johnson & Johnson
JNJ
|
$347.78 B |
-0.005 M
|
USA
|
Novartis
NVS
|
$197.43 B |
0.007 M
|
Switzerland
|
AbbVie
ABBV
|
$300.53 B |
0.002 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
-0.001 M
|
USA
|
Market Cap | = | GUBRA.CO Stock Price | * | GUBRA.CO Shares Outstanding |
= | $87.14 | * | 16.31 M | |
= | $1.42 B |